Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

UCLA's PP405 shows promise in reactivating dormant hair follicles for hair loss treatment but is still in clinical trials. Minoxidil and finasteride remain common treatments until PP405 becomes available.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

A user shared their positive experience with a hair transplant in Bangkok, Thailand, performed by Dr. Kongkiat Laorwong, costing ~$4,500 for 2,100 grafts. The user had been using finasteride, minoxidil, dutasteride, and oral minoxidil for hair loss treatment before the transplant and reported no side effects.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

PP405 may help with hair regrowth, especially when combined with minoxidil and finasteride, but its long-term effectiveness is unclear. Phase 3 trials are expected to begin soon, with results in a few years.

Deoxyribose sugar gel may stimulate hair regrowth similarly to minoxidil by enhancing blood supply and follicle activity. Human trials are necessary, and current products have mixed results.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

A company is developing a topical dutasteride that targets hair follicles without significantly affecting systemic DHT levels, with trials underway to measure its effectiveness. Users discuss the potential benefits and skepticism around the formulation compared to existing treatments.

The conversation discusses obtaining oral minoxidil in Germany, with suggestions to use telemedicine services or visit a dermatologist for a prescription. It also mentions alternatives like buying from Thailand and using topical minoxidil, which is over-the-counter in Poland.

The user plans to start oral finasteride and minoxidil for hair loss and seeks advice on sourcing these medications in the UK. Recommendations include Oxford Online Pharmacy, Dr Fox, and sourcing from India or Thailand for cost savings.

KX-826 and RU58841 are topical anti-androgens discussed for hair loss prevention, with KX-826 showing promise in trials and RU58841 having mixed anecdotal results. Users report combining these with treatments like minoxidil, finasteride, and dutasteride, with varying success and concerns about side effects.

The user has been using oral finasteride and minoxidil for 5-6 months to stop hair loss and is considering a hair transplant. It is suggested to wait 18-24 months for full effects before considering a transplant, with Turkey and Thailand mentioned as cheaper options.

GT20029 is an experimental topical treatment for male-pattern hair loss, showing promising results in Phase 2 trials and moving towards Phase 3. It aims to degrade androgen receptors in hair follicles, differing from treatments like finasteride and minoxidil.

The conversation discusses hair transplant options, comparing the US and Turkey, with suggestions to consider Mexico, Thailand, and other countries. It emphasizes starting treatments like finasteride, minoxidil, and microneedling before proceeding with a transplant.

The conversation discusses the use of Medicube Deoxyribose Gel for hair loss, with skepticism about its effectiveness due to lack of human trials. The original poster uses a combination of minoxidil, finasteride, dutasteride, RU58841, GHK-CU, and is considering adding deoxyribose gel and ketoconazole.

Suvomipic, previously known as PP405, is progressing to Phase 3 trials for hair loss treatment. Its effectiveness compared to existing treatments like Minoxidil and Finasteride is still uncertain.

NOVOGRO's new hair loss treatment is questioned for its effectiveness compared to minoxidil, with skepticism about its claims and trial results. The product targets women and lacks the 5α-reductase inhibitor NV-1065, which is still in development.

2.5mg oral minoxidil can be effective for hair regrowth, but 5mg often shows more dramatic results. Users at Norwood 2 using 1mg finasteride may see modest regrowth with 2.5mg, and it's suggested to give it a proper trial.

The conversation is about skepticism regarding Elon Musk's potential interest in hair cloning and includes unrelated discussions about Epstein and political opinions. Hair cloning is not seen as a trillion-dollar industry unless Elon Musk invests heavily in it.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.